[Synthetic female hormones-induced liver cancer].
Azuma
T
T
Mizumoto
R
R
D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D045166:Estradiol Congeners / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced*; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D009640:Norethindrone / Q000009:adverse effects / Q000031:analogs & derivatives; D000077563:Norethindrone Acetate; D045167:Progesterone Congeners / Q000009:adverse effects*; D051381:Rats; D011919:Rats, Inbred Strains; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use
D003280:Contraceptives, Oral, Synthetic; D045166:Estradiol Congeners; D045167:Progesterone Congeners; D011960:Receptors, Estrogen; D013629:Tamoxifen; D004997:Ethinyl Estradiol; D000077563:Norethindrone Acetate; D009640:Norethindrone